HMGB2 and cancer: In breast (MDA-MB-231, T47D), cervical (SiHa, HeLa), ovarian (SKOV3, OVCAR3), and endometrial (Ishikawa, RL95-2) cancers, HMGB2 knockdown consistently reduced migratory and invasive capacities.